NEW YORK — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check.

The company reduced its fourth-quarter revenue guidance, expecting $13.5 billion, below previous estimates. Despite this, Eli Lilly anticipates strong sales from its weight loss and diabetes drugs.

NEW YORK (AP) — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential ... 221 points, or 0.5%, and the Nasdaq composite ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...

Eli Lilly said Monday it would acquire an experimental cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the pharmaceutical giant broadens its oncology pipeline.

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. The company’s expected 2024 revenue ...

Eli Lilly (LLY) is down -6.5%, or -$51.58 to $745.90. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best ...

Shares of Eli Lilly (NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 ...

Ricks, Lilly chair and CEO ... in a fireside chat at the J.P. Morgan Healthcare Conference later today at 5:15 p.m. Eastern time. A live audio webcast of Ricks' discussion will be available ...

NEW YORK (AP) — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check.